Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for chronic active antibody-mediated rejection in kidney transplant recipients
2019-004302-10Phase 4Active
- Sponsor
- Sahlgrenska University Hospital
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Chronic active antibody-mediated rejection (caABMR) and kidney allograft rejection comparing Tocilizumab + standard of care with Standard of care alone (2 arms). Primary endpoint: Mean rate of change in eGFR from baseline to 24 months. Started Apr 2020; status: active.
02
Drugs
tocilizumab
03
Conditions
Chronic active antibody-mediated rejection (caABMR)kidney allograft rejection
Beyond the preview
Go deeper on 2019-004302-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004302-10.